Browse by author
Lookup NU author(s): Professor Ian McKeith, Dr Dag Aarsland, Professor David BurnORCiD, Professor John O'Brien
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.
Author(s): McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos MacHado J, O'Brien J, Playfer J, Reid W, On behalf of the International Psychogeriatric Association Expert Meeting on DLB
Publication type: Review
Publication status: Published
Journal: Lancet Neurology
Year: 2004
Volume: 3
Issue: 1
Pages: 19-28
ISSN (print): 1474-4422
ISSN (electronic): 1474-4465
URL: http://dx.doi.org/10.1016/S1474-4422(03)00619-7
DOI: 10.1016/S1474-4422(03)00619-7
PubMed id: 14693108
